Jounce Therapeutics Q3 EPS $2.9 Beats $2.24 Estimate, Sales $119.445M Beat $102.34M Estimate

Jounce Therapeutics (NASDAQ:JNCE) reported quarterly earnings of $2.9 per share which beat the analyst consensus estimate of $2.24 by 29.46 percent. This is a 1360.87 percent increase over losses of $(0.23) per share

Benzinga · 11/07/2019 13:50

Jounce Therapeutics (NASDAQ:JNCE) reported quarterly earnings of $2.9 per share which beat the analyst consensus estimate of $2.24 by 29.46 percent. This is a 1360.87 percent increase over losses of $(0.23) per share from the same period last year. The company reported quarterly sales of $119.445 million which beat the analyst consensus estimate of $102.34 million by 16.71 percent. This is a 722.17 percent increase over sales of $14.528 million the same period last year.